Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03573544
Other study ID # OBI-888-001
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date May 7, 2018
Est. completion date April 7, 2022

Study information

Verified date February 2024
Source OBI Pharma, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to establish the maximum tolerated dose (MTD) of OBI-888 as monotherapy. And to characterize the safety and preliminary clinical activity profile of the MTD dose of OBI-888 administered as monotherapy in patients with locally advanced or metastatic solid tumors.


Recruitment information / eligibility

Status Terminated
Enrollment 54
Est. completion date April 7, 2022
Est. primary completion date April 7, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients must meet all of the following criteria in order to be included in the study: 1. Male or female patients, 18 years of age or older at the time of consent. 2. Provide written informed consent prior to performing any study-related procedure. 3. Histologically or cytologically confirmed patients with advanced or metastatic solid tumors for both Dose Escalation and Expansion cohort. 4. Patients must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy. 5. Measurable disease (i.e., at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Adequate organ function defined as: - Hepatic: - Serum alanine aminotransferase (ALT) =3 × upper limit of normal (ULN), =5 × ULN in the presence of liver metastases - Serum aspartate aminotransferase (AST) =3 × ULN, =5 × ULN in presence of liver metastases - Serum bilirubin =1.5 × ULN - Renal: - Creatinine clearance >30 mL/minute using Cockcroft Gault equation - Hematologic: - Absolute neutrophil count =1000/µL - Platelets =75,000/µL - Hemoglobin =8 g/dL 8. Patient is willing and able to comply with all protocol required assessments, visits, and procedures, including pretreatment tumor biopsy. Archival tumor biopsies are acceptable at baseline. 9. Females of childbearing potential must have negative urine or serum pregnancy test prior to starting study therapy, and agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug. Subject not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause. Male patients must agree to use an adequate method of contraception during the study treatment period and for at least 120 days following the last dose of study drug. 10. Cannot be breast feeding. 11. Patients in Part B (Cohort expansion); must have a qualifying, documented Globo H H-score in sponsor-selected tumor types to be enrolled in the respective cohort: - Cohort 1: Pancreatic cancer - Cohort 2: Esophageal cancer - Cohort 3: Gastric cancer - Cohort 4: Colorectal cancer - Cohort 5: Basket (any solid tumor type other than those included in Cohorts 1 through 4) Exclusion Criteria: Patients meeting any of the following criteria are ineligible to participate in this study: 1. Less than 3 weeks, from prior cytotoxic chemotherapy or radiation therapy; and less than 5 half-lives or 3 weeks from biological therapies, whichever is shorter, prior to the first dose of OBI-888. 2. Has undergone a major surgical procedure (as defined by the investigator) or significant traumatic injury within 28 days prior to the first dose of OBI-888. 3. Presence of an active autoimmune or inflammatory disease requiring systemic treatment within the past 2 months or a documented history of clinically severe autoimmune disease that requires systemic steroids or other immunosuppressive medications. Local steroid injections, intermittent use of topical, inhaled, ophthalmologic, intra-articular, topical, or intranasal corticosteroids, or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent would not be excluded from the study. 4. Presence of primary immunodeficiency or receiving systemic steroids of >10 mg/day of prednisone or equivalent or other immunosuppressive agents within 14 days prior to the first dose of OBI 888. 5. Has active bacterial, viral, fungal, or mycobacterial infection requiring systemic therapy, including known infection with human immunodeficiency virus (HIV) or active infection with hepatitis B virus or hepatitis C virus. 6. Patients with a history of solid organ transplant. 7. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03), except for alopecia and laboratory values listed in the inclusion criteria. 8. Receipt of any prior therapy targeting Globo H. 9. Known hypersensitivity to OBI 888 or its excipients. 10. Has known, untreated central nervous system metastases and/or leptomeningeal metastases. 11. Any medical co morbidity or psychiatric illness that is life threatening or, in the opinion of the Investigator, renders the patient unsuitable for participation in a clinical trial due to possible noncompliance, would place the patient at an unacceptable risk and/or potential to affect interpretation of results of the study. 12. Is receiving any concurrent prohibited medication

Study Design


Intervention

Drug:
OBI-888
For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
OBI-888
For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
Device:
Globo H IHC Assay
This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.

Locations

Country Name City State
Taiwan China Medical University Hospital Taichung
Taiwan National Cheng Kung University Hospital Tainan
Taiwan Taipei Veterans General Hospital Taipei
United States West Cancer Center and Research Institute Germantown Tennessee
United States MD Anderson Cancer Center Houston Texas
United States Scripps Clinic Torrey Pines La Jolla California
United States USC/Norris Comprehensive Cancer Center Los Angeles California
United States Rutgers Cancer Institute of New Jersey New Brunswick New Jersey
United States Hoag Memorial Hospital Presbyterian Newport Beach California

Sponsors (1)

Lead Sponsor Collaborator
OBI Pharma, Inc

Countries where clinical trial is conducted

United States,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Benefit Rate (CR, PR, SD) (%) Assessment of OBI-888 clinical benefit rate for dose escalation and cohort expansion phases of the OBI-888-001 study. Every 8 weeks (±1 week) for 6 months, then every 12 weeks (±1 week) until progression or off-study criteria, up to 1 year.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03993873 - Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Phase 1/Phase 2
Recruiting NCT05494918 - First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors Phase 1
Completed NCT02281409 - Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01928459 - Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Phase 1
Completed NCT01449370 - Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer Phase 1
Recruiting NCT06031441 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03059823 - A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT03893955 - A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00878423 - Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors Phase 1
Withdrawn NCT00149019 - Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. Phase 2
Recruiting NCT03093116 - A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Phase 1/Phase 2
Terminated NCT03854227 - A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors Phase 1
Recruiting NCT04094610 - A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Phase 1/Phase 2
Active, not recruiting NCT01543763 - Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Phase 1
Terminated NCT02228811 - A Study of DCC-2701 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05853367 - Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Phase 1
Completed NCT02097810 - Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Phase 1
Recruiting NCT05836324 - A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03910530 - A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT00148993 - Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors Phase 1/Phase 2